Sysmex Europe
Menu

Please select your country. This will keep you up to date with your country-specific information.

Are you aware that 17 April is World Haemophilia Day (WHD)?

Each person has their own experience of coping with haemophilia and other inherited bleeding disorders. 17 April is about increasing the understanding and awareness of haemophilia and other bleeding disorders by sharing those experiences and knowledge with others.

This year, celebrating the 30th WHD, the WFH (World Federation of Hemophilia) is focusing on reaching out and identifying new members of the bleeding disorders community. This awareness matters – since increased awareness and knowledge leads to better diagnosis, living with the bleeding disorders, and access to care for the millions who are currently without treatment. Raise your awareness and support the health of yourself and your loved ones by learning, joining in and taking action with #WorldHemophiliaDay


About Haemophilia
Haemophilia is an x-chromosomal, inherited bleeding disorder caused by a partial or complete deficiency of the coagulation factor VIII (FVIII), so-called ‘haemophilia A’, or coagulation factor IX (FIX), the haemophilia B, leading to a prolongation of the clot formation process. In comparison with von Willebrand disease far fewer people are affected from haemophilia. With a prevalence of 1:5,000 neonates, haemophilia A is more frequent than haemophilia B, which appears in 1:25,000 neonates while von Willebrand disease has a prevalence of 1 percent of the overall population. Haemophilia affects mainly males while females mostly act as carriers of the chromosomal defect. Mutations in factor genes, however, might also affect females showing bleeding tendencies.

Haemophilia is the most frequent haemorrhagic medical condition in children, with significant haemorrhage risks, which can be life-threatening in the absence of immediate treatment. Therefore, laboratory assays play an important role in the detection and management of haemophilia.

The care management of haemophiliacs is changing with the emergence of new treatments. The new therapeutic areas make it necessary to review the present biological and clinical monitoring, where chromogenic FVIII and FIX assays have the advantage of a more homogeneous reactivity to the various FVIII or FIX products available. Depending on the situation, assays with different principles should be considered.

Sysmex offers a complete product portfolio for haemophilia diagnosis and management, which ranges from screening to specialty assays including chromogenic FVIII and FIX assays.

You will soon be able to find more information on haemophilia and our solutions in a SEED article becoming available from May 2019.

Haemostasis

Lab Educational
Documents (SEED)

Haemostasis reagent solutions

Haemostasis products

See the features
See the features
Enjoy our Media Centre
All
  • All
  • Documents
  • Podcast
  • Images
  • Videos
See our collection
Find your job